Title: AST/ALT ratio, APRI, and FIB-4 compared to FibroScan for the assessment of liver
fibrosis in patients with chronic hepatitis B in Bandar Abbas, Hormozgan, Iran
Version: 0 Date: 28 Feb 2023
Reviewer's report:
This manuscript describe that the assessment of liver fibrosis by APRI and FIB-4 correlates with
that by Fibroscan. Unfortunately, however, it is not possible to conclude as the author states
because liver fibrosis assessment by Fibroscan does not always accurately reflect liver fibrosis.
Therefore, we can only conclude that APRI and FIB-4 can achieve similar results without the
use of the Fibroscan, an expensive measuring instrument.
In particular, the assessment of liver fibrosis  by Fibroscan tends to be higher in cases with high
liver inflammation, i.e., high ALT. Therefore, it is an idea to reexamine the results separately
for cases with low ALT and high ALT levels.
Title: AST/ALT ratio, APRI, and FIB-4 compared to FibroScan for the assessment of liver
fibrosis in patients with chronic hepatitis B in Bandar Abbas, Hormozgan, Iran
Version: 0 Date: 28 Feb 2023
Reviewer's report:
This manuscript describe that the assessment of liver fibrosis by APRI and FIB-4 correlates with
that by Fibroscan. Unfortunately, however, it is not possible to conclude as the author states
because liver fibrosis assessment by Fibroscan does not always accurately reflect liver fibrosis.
Therefore, we can only conclude that APRI and FIB-4 can achieve similar results without the
use of the Fibroscan, an expensive measuring instrument.
In particular, the assessment of liver fibrosis  by Fibroscan tends to be higher in cases with high
liver inflammation, i.e., high ALT. Therefore, it is an idea to reexamine the results separately
for cases with low ALT and high ALT levels.
Please review this paper.
user
Title: AST/ALT ratio, APRI, and FIB-4 compared to FibroScan for the assessment of liver
fibrosis in patients with chronic hepatitis B in Bandar Abbas, Hormozgan, Iran
Version: 0 Date: 28 Feb 2023
Reviewer's report:
This manuscript describe that the assessment of liver fibrosis by APRI and FIB-4 correlates with
that by Fibroscan. Unfortunately, however, it is not possible to conclude as the author states
because liver fibrosis assessment by Fibroscan does not always accurately reflect liver fibrosis.
Therefore, we can only conclude that APRI and FIB-4 can achieve similar results without the
use of the Fibroscan, an expensive measuring instrument.
In particular, the assessment of liver fibrosis  by Fibroscan tends to be higher in cases with high
liver inflammation, i.e., high ALT. Therefore, it is an idea to reexamine the results separately
for cases with low ALT and high ALT levels.
assistant